Cue Biopharma, Inc. (CUE): Price and Financial Metrics
GET POWR RATINGS... FREE!
CUE POWR Grades
- Growth is the dimension where CUE ranks best; there it ranks ahead of 56.46% of US stocks.
- The strongest trend for CUE is in Momentum, which has been heading down over the past 31 weeks.
- CUE ranks lowest in Momentum; there it ranks in the 9th percentile.
CUE Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CUE is 0.05 -- better than only 11.11% of US stocks.
- Cue Biopharma Inc's stock had its IPO on January 2, 2018, making it an older stock than only 10.88% of US equities in our set.
- With a price/sales ratio of 109.57, Cue Biopharma Inc has a higher such ratio than 96.73% of stocks in our set.
- Stocks that are quantitatively similar to CUE, based on their financial statements, market capitalization, and price volatility, are FGEN, APTX, ACRS, ARVN, and HRTX.
- Visit CUE's SEC page to see the company's official filings. To visit the company's web site, go to www.cuebiopharma.com.
CUE Stock Price Chart Interactive Chart >
CUE Price/Volume Stats
|Current price||$13.32||52-week high||$28.19|
|Prev. close||$13.47||52-week low||$10.69|
|Day high||$13.60||Avg. volume||408,575|
|50-day MA||$12.95||Dividend yield||N/A|
|200-day MA||$13.75||Market Cap||418.42M|
Cue Biopharma, Inc. (CUE) Company Bio
Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company’s biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.
CUE Latest News Stream
|Loading, please wait...|
CUE Latest Social Stream
View Full CUE Social Stream
Latest CUE News From Around the Web
Below are the latest news stories about Cue Biopharma Inc that investors may wish to consider to help them evaluate CUE as an investment opportunity.
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC
CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of CUE-101 at the recommended Phase 2 dose of 4mg/kg. The Phase 1b portion of the CUE-101 monothera
Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting
CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, which is being held virtually from June 8-11, 2021. Anish Suri, president and chief scientific offi
Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will present at the Jefferies Virtual Healthcare Conference being held June 1-4, 2021. Cue Biopharma will provide a corporate update highlighting clinical progress with CUE-101, representative of the CUE-100 series and the Company’s lead Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform-based therapeutic, in clinical trials for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The presentation will also focus on other platform developments as w...
Cue Biopharma, Inc. ( NASDAQ:CUE ) shareholders should be happy to see the share price up 15% in the last month. But...
Cue Biopharma, Inc. (CUE) Q1 2021 Earnings Conference Call May 17, 2021, 04:30 PM ET Company Participants George Zavoico - VP, IR & Corporate Development Daniel Passeri - CEO & Director Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Matteo Levisetti - SVP,...
CUE Price Returns